Glen Eagle Advisors, LLC Actinium Pharmaceuticals, Inc. Transaction History
Glen Eagle Advisors, LLC
- $546 Billion
- Q2 2024
Shares
3 transactions
Others Institutions Holding ATNM
# of Institutions
76Shares Held
7.05MCall Options Held
96.6KPut Options Held
70.5K-
Black Rock Inc. New York, NY1.88MShares$3.38 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.48MShares$2.66 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA666KShares$1.2 Million0.0% of portfolio
-
State Street Corp Boston, MA610KShares$1.1 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0256KShares$460,8460.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $45.3M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...